Last Updated: November 16, 2026

Details for Patent: 11,649,217

« Back to Dashboard


Which drugs does patent 11,649,217 protect, and when does it expire?

Patent 11,649,217 protects JESDUVROQ and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 11,649,217
Title:Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Abstract:The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
Inventor(s):Minhua Chen, Yanfeng Zhang, Jinqiu WANG, Xiaoyu Zhang
Assignee: GlaxoSmithKline Intellectual Property No 2 Ltd
Application Number:US17/174,006
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 11,649,217

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-001 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-002 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-003 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-004 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-005 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,649,217

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018330994 ⤷  Start Trial
Canada 3112277 ⤷  Start Trial
China 111093668 ⤷  Start Trial
European Patent Office 3682884 ⤷  Start Trial
Spain 2980121 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.